Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL101 in early Alzheimer's disease
NL-OMON60639Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing AL101 dose 1 with Placebo (2 arms). Primary endpoint: Change from baseline in Clinical Dementia Rating - Sum of Boxes at Week 76. Started Oct 2024; status: completed.
02
Drugs
osugacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60639.